Altre lingue Repare Therapeutics Inc.

Azioni

RPTX

US7602731025

Mercato chiuso - Nasdaq Altri mercati azionari 21:59:52 30/05/2024			Variaz. 5gg	Var. 1 gen.
3,36 ^USD	+4,02%		+8,39%	-53,97%

08/05	I migliori guadagni del mercato premarket	MT
07/05	Repare Therapeutics Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024	29/05
Top Premarket Gainers	08/05
Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue	08/05
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results	07/05
Repare Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
DEBIOPHARM AND REPARE THERAPEUTICS ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/1B MYTHIC TRIAL EVALUATING THE SYNTHETIC LETHAL COMBINATION OF WEE1 AND PKMYT1 INHIBITION	01/05
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition	30/04
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition	30/04
DEBIOPHARM ET REPARE THERAPEUTICS ANNONCENT LE TRAITEMENT D’UN PREMIER PATIENT DANS LE CADRE DE L’ÉTUDE DE PHASE 1/1B MYTHIC ÉVALUANT LA COMBINATION D’INHIBITEURS WEE1 ET PKMYT1 GÉNÉRANT UNE LÉTHALITÉ SYNTHÉTIQUE	30/04
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of Wee1 and Pkmyt1 Inhibition	30/04
Repare Therapeutics Inc. Announces Directorate Changes	26/04
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors	26/04
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	21/03
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	15/03
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	12/03
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	03/03
Repare Therapeutics to Participate in Two Upcoming Investor Conferences	29/02
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	28/02
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Repare Therapeutics Inc.

Azioni

RPTX

US7602731025

Altre lingue

Filtri